GLP-1 muscle loss, through menopause:
keep the strength that carries you

Start with what the transition does on its own. In the SWAN cohort (the long-running study of women crossing menopause, with body composition measured by DEXA), the rate of fat gain doubled at the start of the transition and lean mass began to decline, from roughly then until two years after the final period. Total weight showed no acceleration at all: the extra fat and the lost lean cancel out, so the weight line's slope never changes. Falling estrogen sits behind both curves, from perimenopause on. Medicine's name for the muscle side, at its clinical end, is sarcopenia: a diagnosis made in clinics, not a label to self-apply. A GLP-1 adds a large, reliable deficit on top of exactly those years. That is not a reason to avoid the medication. It is the reason the full keep-the-muscle playbook matters more here, not less.

The bone question, with the one trial that measured it

Women in GLP-1 communities ask about bones constantly. Most versions of the question sound like “osteoporosis runs in my family; should I be doing something?” Here is what exists. One randomized trial has measured bone density through GLP-1 weight loss: a year of liraglutide, exercise, both, or placebo, after a low-calorie diet. The combination group lost the most weight, and their hip and spine bone density held, unchanged versus placebo. The medication alone lost more bone density than exercise alone, despite similar weight loss. One drug, one year, one trial: read it as a direction, not a class-wide verdict. But the direction matches the muscle data: the loss is not mandatory, and movement is the lever.

Then the practical fact. The DEXA machine exists in medicine mostly to measure bone density: the body-composition scan you book for fat and lean numbers is its second job, and a whole-body report often carries a bone line. Bild Health reads the composition figures from your scan: fat mass, lean mass, body fat. It does not read or chart bone density: that line belongs to you and your clinician. So keep every report, and if bone is on your mind (family history, an osteopenia flag, a fracture that healed slowly), raise it at the appointment that ordered the scan. Arriving with reports beats arriving with worry.

Exercise, with the trials behind it

The same trial family answered the exercise question twice. The parent study found the exercise-plus-medication combination roughly doubled the drop in body-fat percentage versus either alone, with lean mass held: proof that moving changes what the loss is made of, even though its program was mostly cardio. For holding muscle specifically, resistance training carries the best evidence: in the pooled data, programs that included it cut the lean share of weight lost to 17.5%. Two or three lifting sessions a week that actually progress is the dose the evidence keeps pointing at. Women who lift into their seventies post their results like trophies. They are not wrong to.

What the strength is for

One honest gap: none of the trials above measured physical function. Worth remembering when headlines get loud. But ask women on these medications what they are protecting and the answers are concrete. Carrying a kid on one hip. Getting down on the floor with a toddler and back up without a hand. Groceries, stairs, steadiness on an icy morning. The lean line is the number underneath that list, and watching it hold while the fat line falls is what losing the right weight means. It is a chart, not a feeling. Start with the free protein calculator for the women's numbers, and which scale to trust, and when has its own honest answer.